Proteoglycan(g009) effective in enhancing antitumor immunity
CA 2097820 C · Owner: Il-Yang Pharmaceutical Co. Ltd. · Inventors: Chung, Hoon; Lee, Kwon Haeng; Chung, Chun Hee
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to a proteoglycan G 009 separated from cultured Ganoderma lucidum IY 009 and containing .beta.-glucose, .alpha.-glucose galactose, .alpha.-mannose and fructose as saccharide components, and glycine, alanine, histidine arginine, valine, aspartic acid, threonine isoleucine, serine, leucine, glutamic acid tyrocine, proline, phenylalanine and methionine as protein components. The proteoglycan G 009 exhibits antitumoral and immunostimulating activities.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 4, 1991 and granted May 16, 2000. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 4, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 4, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.